Navigation
Hair Loss News Archives
February 2008
Stem cell and hair loss
Feb 2008
S. Korean stem cell firm enters into an agreement with Tiantan Puhua Neurological Hospital in China
A leading stem cell therapeutics company of Korea, has entered today into an
agreement with Tiantan Puhua Neurological Hospital (Puhua) in Beijing, China to
establish a joint venture (the firm) and a new hospital to provide patients with
stem cell therapeutics.
Dr. Sherwood Yang, Vice president of Puhua agreed with Dr. Jeong Chan Ra,
president of CEO of RNL, to open a new stem cell clinic within Puhua hospital
through the firm.
The new hospital was tentatively named as “RNL-Puhua Stem Cell Medical Center, and will provide stem cell treatments of various degenerative disease including hair loss, aged face and osteoarthritis.
The firm will also supply Puhua hospital with stem cell therapeutics for
neurological condition such as spinal cord injury which Puhua is specialized
for.
“We are very pleased to have a new hospital for stem cell therapy in China. It
will not only advance the commercialization of out stem cell technology but
contribute effective stem cell treatment to patients with obsolete
complications”, said Dr. Ra.
About Tiantan Puhua Neurosurgical Hospital
Tiantan (Temple of Heaven) Puhua (treasure) Neurosurgical Hospital is a
world-class neurological treatment facility in Beijing that is gaining renown as
the world's foremost center for treatment of Parkinson's disease, brain injury,
and a range of other neurological disorders through its groundbreaking stem cell
therapy. To date, Tiantan Puhua Hospital has treated with stem cells over 60
international patients suffering from a range of neurological disorders.
About RNL Bio, CO., LTD.
RNL is a premier biotechnology company in Korea focused on stem cell
therapeutics and life sciences technologies. Headquartered in Seoul with a
recently opened state-of-the-art GMP facility, RNL is a publicly traded company
on the Korean Stock Exchange (Code 003190) and strives to become a global leader
in the development of stem cell therapeutics. In 2006 RNL established wholly
owned US subsidiary, RNL Biostar, for clinical development in the US and for
licensing its technologies in North and South America.